Phase II Trial of Oral LBH 589, a Novel Histone Deacetylase (HDAC) Inhibitor, in Relapsed or Refractory Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma.

Trial Profile

Phase II Trial of Oral LBH 589, a Novel Histone Deacetylase (HDAC) Inhibitor, in Relapsed or Refractory Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 27 Mar 2012

At a glance

  • Drugs Panobinostat (Primary)
  • Indications Chronic lymphocytic leukaemia; Mantle-cell lymphoma
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 27 Mar 2012 Actual end date (Mar 2011) added as reported by ClinicalTrials.gov.
    • 27 Mar 2012 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 07 Apr 2011 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top